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Abstract 34 
Introduction  35 
Botulinum toxin has become a widely adopted treatment for patients with recalcitrant 36 
overactive bladder (OAB) symptoms. Some recommend the institution of clean intermittent 37 
self- catheterisation (CISC) if a post void residual exceeds 200 mls post treatment but there is 38 
no evidence for this recommendation. The aim of this study was to identify whether abstinence 39 
from CISC as a routine strategy for patients with a post void residual (PVR), post intra-detrusor 40 
botulinum toxin injections, is associated with any measureable adversity. 41 
 42 
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Methods  43 
This was a cohort observation study. Patients with lower urinary tract symptoms (LUTS) 44 
attending a medical urology centre were observed pre and post botulinum toxin treatment. 45 
Intra-detrusal botulinum toxin injections were administered in the day treatment centre at a 46 
medical urology centre in London, United Kingdom. Patients were reviewed at follow up 47 
consultations to measure PVR. 48 
 49 
Results  50 
240 patients were studied; there were 215 women and 25 males. 196 patients (82%) received 51 
botulinum toxin injections and were not managed with CISC. 18% were using CISC prior to 52 
injections and continued. None of the 196 developed acute retention or significant voiding 53 
symptoms.  54 
 55 
Conclusions 56 
Our study indicates that routine administration of CISC based on an arbitrary PVR volume is 57 
unlikely to confer benefit. In order to avoid patients being deterred from botulinum treatment 58 
we recommend that CISC be reserved for those who have troublesome voiding symptoms as 59 
well as a raised PVR. It is unlikely that CISC, initiated on the basis of an arbitrary PVR volume 60 
would benefit the patient.  61 
 62 
 63 
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Brief summary 67 
CISC should not be initiated post botulinum toxin injections on the basis of an arbitrary post 68 
void residual, patients will not be harmed. 69 
 70 
Introduction 71 
Intra-detrusal injection of botulinum toxin has become a widely adopted practice in the 72 
treatment of patients with recalcitrant overactive bladder (OAB) symptoms. There is good 73 
evidence of efficacy with improved quality of life (1). The literature recommends  that post-74 
injection, patients found to have a post-void residual (PVR) urine ≥ 150 ml or ≥ 200 ml, should 75 
be started on clean, intermittent self-catheterisation (CISC) (2),  but this discourages patients 76 
from undergoing treatment (3, 4) and some refuse repeat injections because they disliked or 77 
could not perform CISC (2). Given this barrier, it is surprising that there is no published evidence 78 
that justify the prescription of CISC on the indication of a PVR threshold. Why then should we 79 
be recommending an invasive treatment in the absence of evidence to justify it? 80 
Complete urine retention and unpleasant voiding symptoms relieved by CISC would seem 81 
strong indications for CISC. There is a number of consensus statements which define PVR 82 
volumes beyond which CISC should be initiated, but they do not reference evidence of 83 
validation (5). Some might argue that CISC be used to protect against hydronephrosis, as is the 84 
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case after spinal cord injury, but botulinum toxin reduces detrusor contractility (6) obviating the 85 
risk unless complete retention occurs. Thus, there has to be legitimate doubt over whether CISC 86 
confers benefit, or avoids harm to those who have a PVR over a pre-determined threshold, but 87 
we do know that it does cause substantial patient inconvenience (7).  88 
 89 
There have been a number of randomised controlled trials of botulinum toxin injections for 90 
overactive bladder or bladder hyperreflexia. In every case there has been an emphasis on 91 
measuring voiding function post-injection by assessing PVR and in these trials CISC was initiated 92 
for PVR of ≥ 200 ml, and in one case ≥ 150 ml (3, 8-12).  In none of these studies was a 93 
justification or explanation offered for the choice of threshold for initiating CISC.  94 
We observed a number of patients who declined CISC, despite an increased PVR, after 95 
botulinum toxin injection, and noted that they came to no harm. Given the absence of 96 
evidence, we ceased to recommend CISC based on an arbitrary PVR. We reserved the method 97 
for patients who developed acute retention or symptoms of retention reversed by CISC and for 98 
patients already using CISC prior to botulinum toxin treatment. 99 
 100 
If clinicians wish to recommend CISC based on a PVR, then data from an RCT should justify this. 101 
Prior to embarking on an RCT it is necessary to know whether an effect is likely to be detected 102 
and if so, what is the likely size. No such data exists, so before considering an RCT the first task 103 
must be an observational study to discover a priori whether there is a problem for CISC to 104 
remedy anyway. We set out to ascertain whether patients, post-botulinum toxin injection, 105 
experience any measurable harm when not using CISC regardless of the PVR. The aim of this 106 
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study was to identify whether abstinence from CISC as a treatment, post intra-detrusor 107 
botulinum toxin injections, in patients with a post void residual, was associated with any 108 
measureable adversity. 109 
 110 
Materials and Methods 111 
The study was approved by Noclor Research London – St Pancras Reference-168107. This was a 112 
cohort observation which began in June 2011 lasted until January 2013. Patients with lower 113 
urinary tract symptoms (LUTS) attending a medical urology centre in London were observed pre 114 
and post botulinum toxin treatment. Male and female patients diagnosed with refractory 115 
overactive bladder (OAB), unresponsive to antimuscarinic agents with bladder retraining and 116 
who were offered botulinum toxin injections as treatment were observed. OAB symptoms were 117 
diagnosed using a validated hybrid international consultation on incontinence questionnaire 118 
(ICIQ) and female lower urinary tract symptoms questionnaire (FLUTS), with sections of the 119 
questionnaire focusing on urinary frequency and urgency symptoms.  Patients were given an 120 
information sheet about the botulinum toxin treatment and were provided with a counselling 121 
session, and an opportunity to ask questions and address any concerns about the treatment. 122 
Patients were informed about the risks associated with the intervention and were given a 123 
choice over local or general anaesthetic. A written informed consent was obtained. Consented 124 
patients were later put on the surgical list for botulinum toxin injections.  125 
 126 
Intra-detrusal botulinum toxin injections were administered in the day-treatment centre at a 127 
north London hospital by two different Consultant Gynaecologists on various days. Patients 128 
7 
 
were administered Allergan (Botox A) 200 IU, injected in 20x 1ml aliquots, in an array pattern 129 
and sparing the trigone. 200 IU was the standard dose administered according to local clinical 130 
guidelines and authorised by the chief pharmacist and medicines management committee at 131 
the hospital trust. A dose less than 200 IU had been audited as ineffective with patients 132 
requiring frequent subsequent injections. The injections were placed in the detrusor muscle 133 
rather than just under the urothelium and mainly in the base and sidewalls of the bladder 134 
(avoiding the trigone) as this is where the bladder afferents are clustered. Two weeks later the 135 
patients were reviewed and during the interim they continued with prior antimuscarinic 136 
therapy. They had the option of earlier contact with the medical urology centre if necessary. At 137 
follow-up consultations patients were asked about specific side effects; voiding dysfunction and 138 
symptoms of infection. The ICIQ-FLUTS questionnaire, which focuses on urinary frequency, 139 
urgency symptoms; stress symptoms, voiding symptoms, pain symptoms and quality of life was 140 
used to analyse patient symptoms. The symptom set is described in Figure 1 which 141 
demonstrates the distribution of the symptoms. Patients provided a midstream urine specimen 142 
for dipstick analysis, light microscopy for pyuria and routine culture; a bladder scan was 143 
conducted to measure post-void residual. This was the assessment protocol carried out during 144 
each follow up consultation and patients were treated for a urinary tract infection, if it was 145 
diagnosed. 146 
 147 
Patients with a post void residual of ≥ 150mls had a blood sample obtained to measure 148 
creatinine and monitor kidney function. A creatinine of between 70- 120 mcmol/L was accepted 149 
according to local clinical guidelines, patients not within those parameters were required to 150 
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have a renal tract scan to detect the probability of hydronephrosis. Patients who were unable 151 
to void, or had used CISC preoperatively were managed with CISC. In all other cases this 152 
technique was not advocated unless a patient described clear, troublesome voiding symptoms 153 
that were relieved by removal of residual urine. In such cases, CISC was taught in a private 154 
consultation room. Patients were given an information sheet on how to perform CISC and were 155 
also given verbal instructions on the principles and technique of catheter insertion and 156 
informed about infection control management. Patients were routinely followed up in the 157 
outpatients department two weeks after the first botulinum treatment, followed by four weeks, 158 
then six weeks and lastly eight weeks. The same assessments and checks were repeated at each 159 
visit. Patients had the opportunity to attend the department earlier if they were concerned or 160 
had LUTS. The sample size was calculated using G*Power© version 3.1.9.2 using the Wilcoxon-161 
Mann-Whitney- test method. The smallest, clinically significant effect size, that would justify 162 
changing practice, was estimated as 3 symptoms from a score that measured 39 symptoms, 163 
where normal persons described zero symptoms. The estimate drew on data obtained from an 164 
observational study of treatment of patients with OAB (13). This gave a Cohen’s d (𝑑 =
𝑥1 − 𝑥2 
𝑆
) 165 
d = 0.65; α = 0.05; Power (1 – β) = 0.8 or 80%. We required a minimum of 40 patients. 166 
Recruitment had continued until this was achieved. 167 
 168 
Results  169 
240 patients were studied; there were 215 women and 25 males. The mean age of the women 170 
was 57.6 years sd=14.7; the mean age of the males was 49.1 sd=14.4 the difference being 171 
insignificant. The distribution of the LUTS symptoms measured after the botulinum treatment 172 
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and their overlap are shown in the Venn diagram of Figure 1. 43 of the 240 patients (18%) used 173 
CISC prior to treatment and continued to use it afterwards. 12 patients (5%) had medical 174 
histories of autonomic neuropathy, spina bifida, cerebrovascular disease or multiple sclerosis. 175 
31 patients (13%) who were using CISC prior to treatment sustained voiding symptoms after 176 
receiving botulinum toxin injections. These symptoms were reported as troublesome and 177 
relieved by continued use of CISC. 196 patients (82%) that were not managed with CISC were 178 
reviewed serially and saw their residual urine gradually subside over time. They did not develop 179 
voiding symptoms or urinary retention after botulinum toxin injections and were not managed 180 
with CISC. There were many similarities in the baseline data between patients in the CISC group 181 
and the non-CISC group (Table 1). Thus the mean duration of symptoms for groups was 7.35 182 
years (sd=3.8). They also described similar numbers of 24-hour incontinence episodes (Mean = 183 
2.8; sd = 2); a similar number of pain symptoms (mean= 0.57; sd= 0.976) and similar numbers of 184 
urgency symptoms (mean=5.5; sd=3). The number of voiding symptoms was higher in patients 185 
from the non-CISC group (average number of symptoms = 7.3, sd= 4.8), compared to the CISC 186 
group (average number of symptoms = 7.0, sd= 5.5). The CISC group appeared to have more 187 
stress incontinence symptoms (average number of symptoms = 3, sd= 2.6. median = 4.0) 188 
compared with the non-CISC group (average number of symptoms = 0.75, sd= 1.0, median = 189 
0.5) but this was not statistically significant (Mann Whitney U = 1986, p = .74). The comparison 190 
has been shown in table 2 and 3.  191 
 192 
After the botulinum toxin injection there was no significant difference in residual urine between 193 
patients who used CISC (mean = 2.2 ml, sd= 8.8, median = 0) and those who did not (mean = 20, 194 
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sd= 55, median = 0) (Mann Whitney U = 1222, p = .29). The combined residual urine amount in 195 
patients using CISC was 111 ml (95% CI= 68 to 1544; Max = 1400 ml, Range= 20 ml). This is 196 
illustrated in Figure 2.  For those not using CISC the combined residual urine amount was 82 ml 197 
(95% CI= 73 to 90 ml; Max = 1100, Range= 10 ml) again the difference was not statistically 198 
significant (Mann Whitney U = 70786, p=.77). Those not using CISC manifested a wide variance 199 
which is seen by comparing Figure 3.                           200 
                        201
Figure 4 plots the symptoms scores of the 240 patients within the observation and the average 202 
total. The ICIQ-FLUTS questionnaire was used as an assessment tool at each follow up visit. 203 
There was a significant fall of symptoms at the first visit post botulinum injection which was 204 
maintained at the second review visit. There was a return of symptoms at the third and fourth 205 
visit after the injection. There were no between-group differences in urgency, the patients’ 206 
assessment of treatment response, frequency, incontinence, voiding, or pain symptoms. There 207 
were no differences in pyuria or positive urine culture, and no evidence of differences in renal 208 
biochemistry at any stage during follow-up. At the third and fourth clinic review, symptoms of 209 
urinary urgency became dominant. Figure 5 illustrates the urgency symptoms indicating a need 210 
for another botulinum toxin treatment. Patients who had an elevated PVR (>150 ml) and did 211 
not commence on CISC saw the residual decrease with each visit (Figure 3) in contrast to those 212 
using CISC (Figure 2). The patients who did not use CISC, including all those with a PVR ≥ 150 ml 213 
failed to demonstrate any symptoms, sign or pathology that would be amenable to CISC.  214 
 215 
 216 
11 
 
Discussion 217 
Current clinical practice advocates the use of CISC based on a PVR of 150 ml or more. This is an 218 
arbitrary criterion which is not based on evidence. We used CISC but only in patients who had 219 
appropriate symptoms that were demonstrably relieved by CISC. Thus, a number of our 220 
patients lived with significant urine residuals volumes, well over 150 ml, during the weeks after 221 
the botulinum toxin injection. They appeared to come to no harm such a hydronephrosis or 222 
urinary retention. This is important because many are denied the option of botulinum injection 223 
because of fears of these conditions after the injections. These data imply that these fears may 224 
be exaggerated. This study has its limitations. We were not blinded; we did not measure the 225 
quality of life, nor was this a randomised controlled trial. To some extent we should be 226 
reassured over bias arising from the lack of blinding because we used and objective measure 227 
(PVR) that behaved in an appropriate manner by falling during the weeks after injection. These 228 
data render an RCT extremely difficult to justify because we failed to detect significant adversity 229 
in the group who did not use CISC. Thus we are not able to propose a plausible outcome 230 
measure, nor are we able to offer a variable that could be used in a sample size estimate. If 231 
observational data cannot detect a significant outcome, an RCT would be less likely to achieve 232 
this.  233 
 234 
The study was motivated by patient preference, following experiences with patient coming to 235 
no harm despite refusing CISC after a significant PVR was detected. CISC is avoidable by 236 
ensuring that patients are frequently monitored and assessed for retention symptoms post 237 
treatment. Many patients are alarmed at the prospect of CISC and state that they would be 238 
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reluctant to take this on with the result that they do not receive botulinum toxin treatment. 239 
This study has led us to a different approach to consent. We explain that we shall do our utmost 240 
to avoid using CISC, despite degrees of retention, and should only use it for limited periods if a 241 
symptomatic retention occurred. This seems to be a palatable risk for our patients and more 242 
therefore consent to the treatment. Introducing CISC should be based on individual symptom 243 
assessments following treatment. A patient reporting troublesome voiding symptoms such as 244 
hesitancy, reduced stream, intermittent stream and straining to void should be considered for 245 
CISC but this study indicates that patients without such symptoms are unlikely to benefit. 246 
 247 
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